trending Market Intelligence /marketintelligence/en/news-insights/trending/RRwmmxXwKJwN-nffJSGvjA2 content esgSubNav
In This List

Pfizer buys another NC facility to expand gene therapy manufacturing capacity

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Pfizer buys another NC facility to expand gene therapy manufacturing capacity

Pfizer Inc. has bought another gene therapy manufacturing facility in North Carolina near one the pharmaceutical giant is revamping in Sanford, according to a report from Fierce Pharma.

The New York-based company paid about $19 million to buy a piece of land and a finished building in Durham, N.C., that is equipped to house about 120 employees. The new Advanced Therapy Medicinal Product facility is expected to be completely constructed and retrofitted by 2022, according to the report.

Gene therapies require specific virus vectors to be custom-made, which requires state-of-the-art equipment.

Pfizer announced in August that the company will spend $500 million to update a gene therapy manufacturing facility in Sanford, N.C., adding about 300 new jobs there.

Pfizer employs more than 3,600 people in North Carolina, 650 of whom are in Sanford.